MindMed Announces Publication of Study Comparing Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects

NEW YORK, March 2, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain disorders, announced today publication of a study directly comparing the acute effects of lysergic acid diethylamide (LSD) and psilocybin in healthy subjects. The data, published in Neuropsychopharmacology and titled “Direct Comparison of Acute Effects of Lysergic Acid Diethylamide and Psilocybin in a Double-Blind, Placebo-Controlled Study in Healthy Subjects“, demonstrates that the main differences between LSD and psilocybin are dose-dependent rather than substance-dependent. psychedelic therapy.

“The results of this publication continue to expand our knowledge of the differences between LSD and psilocybin with respect to their acute effects, similarities and dose equivalence,” said Prof. Matthias Liechti MD., University Hospital Basel, principal investigator of the study. “Although both substances are used as pharmacological tools, there are no modern studies directly examining and comparing the acute effects of these substances in the same clinical study, using well-defined doses and validated psychometric tools. Together, these results suggest that 20 mg of psilocybin is equivalent to 100 μg of LSD, and 30 mg of psilocybin is equivalent to 150 μg of LSD, making the dose equivalence of LSD to psilocybin approximately 1:200. Surprisingly, there were no qualitative differences in altered states of consciousness between the substances, except that the duration of action was shorter for psilocybin.”

Miri Halperin WernliPh.D., Executive Chairman of MindMed, added, “LSD and psilocybin have recently emerged as promising candidates for the treatment of various psychiatric and neurological disorders, and hence a deeper understanding of their differential subjective effects in humans. is necessary. This study brings us one step closer to maximizing the therapeutic potential of these molecules, providing valuable dose-finding context and enabling more direct comparisons when interpreting clinical results. These insights will help guide our program. progressing clinical development, and we look forward to providing updates as we work to bring the benefits of psychedelic-inspired drugs to patients with brain disorders.”

In this double-blind, randomized, placebo-controlled crossover design, researchers evaluated twenty-eight healthy participants who underwent five 25-hour sessions and received placebo, LSD (100 and 200 mcg), and psilocybin (15 and 30 mg). The test days were spaced at least 10 days apart. Outcome measures included self-report scales of subjective effects, autonomic effects, adverse effects, durations of effect, plasma levels of brain-derived neurotrophic factor (BDNF), prolactin, cortisol and d oxytocin, and pharmacokinetics.

The study characterized the effects of LSD and psilocybin at two different doses and showed that the two doses of LSD and the high dose of psilocybin produced qualitatively and quantitatively similar subjective effects, indicating that mind alterations do not not differ beyond the duration of the effect. As expected, the 200 mcg dose of LSD induced higher rates of ego dissolution, anxiety, as well as impaired control and cognition, compared to the 100 mcg dose of LSD. The 200 µg dose of LSD increased ineffability rates significantly more than 30 mg of psilocybin. Interestingly, LSD at both doses had significantly longer durations of effect than psilocybin. Taken together, these results suggest that the 20 mg dose of psilocybin is likely equivalent to the 100 µg dose of LSD. Beyond the subjective effects, LSD and psilocybin showed comparable cardio-stimulating properties, as assessed by the rate-pressure product.

MindMed retains executive rights to the data from this investigator-initiated study conducted at University Hospital Basel.

About MindMed

MindMed is a clinical-stage psychedelic medicine biotechnology company that seeks to discover, develop and deploy psychedelic-inspired drugs and therapies to combat addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative psychedelic-based treatments including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. MindMed’s leadership team brings extensive biopharmaceutical experience to MindMed’s approach to developing the next generation of psychedelic-inspired drugs and therapies.

MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

Forward-looking statements

Certain statements in this press release relating to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are forward-looking in nature. Forward-looking information is not based on historical fact, but rather on current expectations and projections regarding future events and is therefore subject to risks and uncertainties that could cause actual results to differ materially from future results. expressed or implied by the forward-looking statements. . There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including historical negative cash flows; limited operating history; occurrence of future losses; availability of additional capital; lack of revenue from products; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; increased regulatory control; early stage product development; risks associated with clinical trials; regulatory approval processes; the novelty of the psychedelic-inspired drug industry; together with the risk factors discussed or referred to herein and the risks described under the headings “Risk Factors” in the Company’s filings with securities regulatory authorities in all provinces and territories of Canada which are available under the Company’s profile on SEDAR at www.sedar.com and with the United States Securities and Exchange Commission on EDGAR at www.sec.gov.

SOURCE Mind Medicine (MindMed) Inc.

Jacob L. Thornton